Charles River Laboratories | CRL - Interest Expense On Debt

Stock Price
200.43
Daily Change
-0.98 -0.49%
Monthly
-3.79%
Yearly
20.84%
Q1 Forecast
204.00

Charles River Laboratories reported $25.4M in Interest Expense on Debt for its fiscal quarter ending in September of 2025.





Interest Expense On Debt Change Date
Agilent USD 27M 1000K Sep/2025
Align Technology USD 2M 660K Mar/2023
Bio-Rad Laboratories USD 12.3M 100K Sep/2025
Bruker USD 20M 4.3M Sep/2025
Cardinal Health USD 80M 6M Sep/2025
Charles River Laboratories USD 25.4M 4.56M Sep/2025
Cigna USD 157.92B 157.58B Sep/2025
CVS Health USD 784M 21M Sep/2025
Danaher USD 55M 12M Dec/2025
Dentsply International USD 23M 1000K Sep/2025
Elevance Health USD 366M 15M Dec/2025
Galapagos EUR 1.72M 940K Sep/2025
Hologic USD 27.6M 1000K Dec/2025
Humana USD 168M 11M Sep/2025
Illumina USD 25M 0 Jun/2025
Incyte USD 592K 2K Sep/2025
IQVIA Holdings USD 189M 7M Sep/2025
Laboratory Of America USD 56M 1.1M Sep/2025
Lonza CHF 84M 14M Jun/2025
McKesson USD 74M 25M Sep/2025
Merck EUR 126M 47M Sep/2025
Mettler Toledo International USD 17.7M 916K Sep/2025
Novartis USD 281M 8M Sep/2025
Pfizer USD 711M 59M Dec/2025
Quest Diagnostics USD 69M 2M Sep/2025
Revvity USD 22.77M 166K Sep/2025
Thermo Fisher Scientific USD 365M 18M Dec/2025
United Therapeutics USD 3M 4.3M Sep/2025
UnitedHealth USD 974M 29M Dec/2025
Waters USD 26.64M 12.28M Sep/2025
West Pharmaceutical Services USD 200K 100K Sep/2025